title: Pharmacological treatment of obsessive-compulsive disorder.
abstract: Obsessive-compulsive disorder (OCD) affects up to 2.5% of the population of the course of a lifetime and produces substantial morbidity. Approximately 70% of patients can experience significant symptomatic relief with appropriate pharmacotherapy. Selective serotonin reuptake inhibitors are the mainstay of pharmacological treatment. These drugs are typically used at higher doses and for longer periods than in depression. Proven second-line treatments include the tricyclic clomipramine and the addition of low-dose neuroleptic medications. OCD refractory to available treatments remains a profound clinical challenge.
authors.affiliation: Department of Psychiatry and Child Study Center, Yale University School of Medicine, 34 Park Street, New Haven, CT 06519, USA. Electronic address: Christopher.pittenger@yale.edu.
authors.forename: Christopher
authors.initials: C
authors.lastname: Pittenger
authors.affiliation: Department of Psychiatry and Child Study Center, Yale University School of Medicine, 34 Park Street, New Haven, CT 06519, USA.
authors.forename: Michael H
authors.initials: MH
authors.lastname: Bloch
mesh_terms: D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D006801:Humans; D004366:Nonprescription Drugs / Q000627:therapeutic use*; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000235:genetics / Q000628:therapy; D057285:Precision Medicine; D011613:Psychotherapy; D011619:Psychotropic Drugs / Q000627:therapeutic use*
chemical_list: D004366:Nonprescription Drugs; D011619:Psychotropic Drugs
keywords: Antidepressant; Augmentation; OCD; Obsessive-compulsive disorder; Pharmacotherapy; SSRI